Stryker Corp had a decent result with a good performance in terms of organic sales. The company’s financial performance was driven by exceptional double-digit growth from its Neurotechnology and MedSurg businesses, but this was offset by softer sales of the spine, knee, and hip because of the resurgence of the pandemic. Though its implant business diminished, the company saw the robust result for its capital products and Mako product technology over its MedSurg portfolio. A slowdown in deferrabl ....
27 Apr 2022
Stryker Corporation: Financial & Price Forecasts, DCF Valuation, ESG & Other Risks (04/22)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Stryker Corporation: Financial & Price Forecasts, DCF Valuation, ESG & Other Risks (04/22)
- Published:
27 Apr 2022 -
Author:
Ishan Majumdar -
Pages:
16
Stryker Corp had a decent result with a good performance in terms of organic sales. The company’s financial performance was driven by exceptional double-digit growth from its Neurotechnology and MedSurg businesses, but this was offset by softer sales of the spine, knee, and hip because of the resurgence of the pandemic. Though its implant business diminished, the company saw the robust result for its capital products and Mako product technology over its MedSurg portfolio. A slowdown in deferrabl ....